Stifel Nicolaus rated Buy ARDEA BIOSCIENCES (NASDAQ: RDEA) on 07/01/2011, when the stock price was $25.49. Since then, ARDEA BIOSCIENCES has gained 25.38% as of 06/19/2012's recent price of $31.96.
If you would have followed this Stifel Nicolaus's recommendation on RDEA, you would have gained 25.38% of your investment in 354 days.

Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA594 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation.

Stifel Nicolaus research focuses on all market caps, but is a leader in small- and mid-cap research. The department is staffed predominately with industry professionals from outside Wall Street. In fact, approximately 50% of its analysts have hands-on work experience in the industry that they research. Stifel Nicolaus believes industry experience, its opportunistic approach, and broad market cap coverage drive excess returns and its award-winning franchise.

Marked as spam